1. Executive Summary 2. United States Diabetes Population, and Forecast, 2015 – 2027 3. United States Insulin Users Volume, and Forecast, 2015 – 2027 4. United States Blood Sugar Lancet Users Volume Assessment, and Forecast, 2015 – 2027 5. United States Blood Sugar Lancet Market Analysis, Insights, and Forecast, 2015 – 2027 6. Key Market Drivers and Inhibitors of the United States Blood Sugar Lancet Market 6.1 Market Drivers 6.2 Market Inhibitors 7. Reimbursement Environment of the United States Blood Sugar Lancet Market 8. Regulatory Framework of the United States Blood Sugar Lancet Market 9. Key Companies Profiles (Overview and Key Marketed Products) 9.1 Sanofi 9.2 Life Scan, Inc 9.3 Roche 9.4 Omron 9.5 Fifty50 Medical 9.6 iHealth Labs 9.7 Omnis Health 9.8 Arkray, Inc 9.9 ForaCare, Inc 9.10 Trividia Health, Inc 9.11 Ypsomed Holding AG 9.12 Abbott Diabetes Care 9.13 AgaMatrix, Inc 9.14 Nova Diabetes Care, Inc 9.15 B. Braun Holding GmbH & Co. KG 9.16 Entra Health (Acquires by CRF Health)

List of Tables: Table 6–1: Worldwide Healthcare Spending on Diabetes (Billion US$), 2015 & 2040 List of Figures: Figure 2–1: United States Diabetes Population (Thousand), 2015 – 2019 Figure 2–2: United States Diabetes Population Forecast (Thousand), 2020 – 2027 Figure 3–1: United States Insulin Users (Thousand),2015 – 2019 Figure 3–2: United States Insulin Users Forecast (Thousand),2020 – 2027 Figure 4–1: United States Blood Sugar Lancet Users Volume Assessment (Thousand), 2015 – 2019 Figure 4–2: United States Blood Sugar Lancet Users Volume Assessment Forecast (Thousand), 2020 – 2027 Figure 5–1: United States Blood Sugar Lancet Market (Million US$), 2015 – 2019 Figure 5–2: United States Blood Sugar Lancet Market Forecast (Million US$), 2020 – 2027